TCV-116, an angiotensin II type 1 receptor antagonist, reduces hepatic ischemia-reperfusion injury in rats

Transplantation

Volumn 73, Issue 4, 2002, Pages 529-534

  Araya, Jun ^a   Tsuruma, Tetsuhiro ^a   Hirata, Koichi ^a   Yagihashi, Atsuhito ^a   Watanabe, Naoki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ASPARTATE AMINOTRANSFERASE; CANDESARTAN HEXETIL; CREATINE KINASE; CYTOKINE; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT; INTERLEUKIN 6; LACTATE DEHYDROGENASE; SCATTER FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CYTOKINE PRODUCTION; DRUG MECHANISM; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER INJURY; LIVER ISCHEMIA; LIVER SURGERY; LIVER TRANSPLANTATION; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY;

EID: 0037181106     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200202270-00006     Document Type: Article

References (56)

1. Doxorubicin preconditioning: A protection against rat hepatic ischemia-reperfusion injury
2. Oxygen-derived free radicals in postischemic tissue injury
3. Calcium and ischemic injury
4. Adenosine nucleotide metabolism during hepatic ischemia and subsequent blood reflow periods and its relation to organ viability
5. 10
6. Beneficial effect of cyclosporine pretreatment in canine liver ischemia: Enzymatic and electronmicroscopic studies
7. FK 506 ameliorates the hepatic injury associated with ischemia and reperfusion in rats
8. Protective effects of the calcium channel blocker verapamil on hepatic function following warm ischemia
9. Hypertensive vascular disease produced by homologue rennin
10. Acute renal failure, tubular necrosis and myocardial infraction induced in the rabbit by intravenous angiotensin II
11. Essential hypertension: Rennin and aldosterone, heart attack and stroke
12. Relation of plasma renin to end organ damage and to protection of K feeding in stroke-prone hypertensive rats
13. Enalapril prevents stroke and kidney dysfunction in salt-loaded stroke-prone spontaneously hypertensive rats
14. Chronic effects of enalapril on blood pressure, stroke, plasma rennin, urinary electrolytes and PGE2 excretion in stroke-prone spontaneously hypertensive rats
15. Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats
16. 2-receptor activation, bradykinin and prostaglandins in pigs
17. Nonpeptide angiotensin II receptor antagonist. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids
18. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist
19. Angiotensin II-forming pathways in normal and failing human hearts
20. Conversion of angiotensin I to angiotensin II in dog isolated renal artery: Role of two different angiotensin II-generating enzymes
21. Antihypertensive effects of a highly potent and long acting angiotensin II subtype-1 receptor antagonist, (±)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-l-((2′- (1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1H-benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats
22. Effects of the non-peptide angiotensin II receptor antagonist TCV-116 on systemic and renal hemodynamics in dogs with renal hypertension
23. Effects of captopril on ischemic events after myocardial infarction: Results of the survival and ventricular enlargement trial
24. ISIS-4: A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction
25. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
26. Angiotensin-converting enzyme inhibition by enalapril: A novel approach to reduce ischemia/reperfusion damage after experimental liver transplantation
27. The role of angiotensin receptors in cardiovascular disease
28. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells
29. Evaluation of serum IL-8 concentrations after orthotopic liver transplantation in rats
30. Angiotensin II receptor antagonists
31. Hepatic resection with ischemia of the liver exceeding one hour
32. Multiple-system organ damage resulting from prolonged hepatic inflow interruption
33. Reperfusion injury after liver preservation for transplantation
34. Role of neutrophils in generalized reperfusion injury associated with resuscitation from shock
35. Liver ischemia and reperfusion induces a systemic inflammatory response through Kupffer cell activation
36. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin-1
37. Tumor necrosis factor-mediated release of platelet-derived growth factor from culture endothelial cells
38. Cachectin/TNF as well as interleukin-1 induces prostacyclin synthesis in cultured vascular endothelial cells
39. Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-alpha, LPS and IL-1 beta
40. Tumor necrosis factor up-regulates intercellular adhesion molecule 1, which is important in the neutrophil-dependent lung and liver injury associated with hepatic ischemia and reperfusion in the rat
41. Intercellular adhesion molecule 1 (ICAM-1) expression and its role in neutrophil-induced ischemia-reperfusion injury in rat liver
42. Chemokine expression during hepatic ischemia/reperfusion-induced lung injury in the rat. The role of epithelial neutrophil activating protein
43. Chemokine involvement in hepatic ischemia/reperfusion injury in mice: Roles for macrophage inflammatory protein-2 and KC
44. Enhanced pulmonary expression of CXC chemokines during hepatic ischemia/reperfusion-induced lung injury in mice
45. An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin-1, and tumor necrosis factor alpha increases neutrophil adherence by a CDW18-dependent mechanism
46. Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors
47. Leukocyte stasis in hepatic sinusoids
48. Purification and subunit structure of hepatocyte growth factor from rat platelets
49. Emerging multipotent aspects of hepatocyte growth factor
50. Recombinant human hepatocyte growth factor protects the liver against hepatic ischemia and reperfusion injury in rats
51. Intravenous injection of an adenovirus encoding hepatocyte growth factor results in liver growth and has a protective effect against apoptosis
52. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways
53. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF
54. Met/HGF receptor modulates bcl-w expression and inhibits apoptosis in human colorectal cancers
55. Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters
56. Prevention of renal damage by angiotensin II blockade, accompanied by increased renal hepatocyte growth factor in experimental hypertensive rats